Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction:

Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central regulator of this multi-organ syndrome.

Why was this review needed?

Current CKM management focuses on treating individual organs rather than the underlying disease network. Growing evidence suggests that gut dysbiosis and reduced butyrate production may drive inflammation, insulin resistance, and cardiorenal dysfunction, creating new opportunities for microbiota-targeted therapy.

What did the review show?

• Loss of butyrate-producing bacteria is consistently associated with CKM syndrome.
• Butyrate improves insulin sensitivity and reduces chronic metabolic inflammation.
• It protects against oxidative stress, endothelial dysfunction, and excessive RAAS activation.
• Butyrate helps maintain intestinal barrier integrity and restores gut microbial balance.
• Dietary fiber, direct butyrate supplementation, and microbiota-directed therapies all show potential to increase butyrate availability.
• The authors propose a novel gut–butyrate–CKM axis, positioning butyrate as a key mediator linking gut health with cardiovascular, renal, and metabolic function.

Clinical Impact:

This review shifts the focus from treating individual CKM components to targeting a common upstream mechanism. Microbiota-based interventions that restore butyrate production may become valuable adjuncts in preventing and managing CKM syndrome.

Take-Home Message:

Butyrate is emerging as a central molecular link between gut health and cardiovascular, kidney, and metabolic diseases. Restoring butyrate-producing bacteria through diet or microbiota-targeted therapies may represent a promising new strategy for integrated CKM management.